Integra Lifesciences Holdings Corp
A maker of surgical and medical devices used by neurosurgeons, reconstructive surgeons, and general surgeons. Its best-known product is the Integra Dermal Regeneration Template, a bioengineered "artificial skin" scaffold that helps severe burn victims grow new skin. The company was founded in 1989 by Dr. Richard Caruso, who licensed the collagen-scaffold technology developed at MIT and Harvard. Its name reflects the product's purpose: the matrix integrates with the patient's own body to regenerate tissue.
Granted 45.7K · Bought 52.6K
Granted 62.7K · Bought 36.4K
Granted 35.2K
Granted 28.3K
Granted 8.7K
Granted 45.2K · Sold 8.3K
Granted 42.5K · Sold 1.7K
Granted 18.6K · Sold 4.1K
Granted 41.0K
Granted 28.3K
Granted 32.1K · Bought 9.0K
Granted 46.3K
Granted 28.3K
Granted 20.1K · Sold 1.2K
Granted 20.8K
Granted 33.1K
Granted 1.4K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Essig StuartDirector · 7 transactions | — | 2.67Mas of Aug 2025 | 45.7K | 52.6K | — |
| Hill Barbara BDirector · 7 transactions | — | 187.5K | 62.7K | 36.4K | — |
| Schade Christian SDirector · 3 transactions | +64.3% | 90.0Kas of May 2025 | 35.2K | — | — |
| Bradley KeithDirector · 6 transactions | +43.2% | 88.3K | 28.3K | — | — |
| Murphy Raymond G.Director · 1 transaction | +11.7% | 82.8Kas of May 2024 | 8.7K | — | — |
| Davis Robert T. Jr.EVP & President, TT · 16 transactions | +45% | 66.4K | 45.2K | — | 8.3K |
| McBreen Michael J.EVP & President, CSS · 17 transactions | +42.1% | 60.7K | 42.5K | — | 1.7K |
| Schwartz EricEVP, Chief Legal Officer & Sec · 11 transactions | +15.3% | 56.0Kas of Mar 2025 | 18.6K | — | 4.1K |
| Knight Lea DanielsEVP & Chief Financial Officer · 7 transactions | +176% | 50.5K | 41.0K | — | — |
| Clay ShaundraDirector · 2 transactions | +213.9% | 41.5Kas of May 2025 | 28.3K | — | — |
| Graves Jeffrey ADirector · 5 transactions | — | 41.1K | 32.1K | 9.0K | — |
| Singh HarvinderEVP & PRESIDENT, INTERNATIONAL · 13 transactions | — | 40.6K | 46.3K | — | — |
| Lo Renee WonlaiDirector · 2 transactions | +379.5% | 35.7Kas of May 2025 | 28.3K | — | — |
| Mosebrook JeffreySVP, Fin & Princ Acct Officer · 18 transactions | +51.1% | 35.5K | 20.1K | — | 1.2K |
| De Witte JanPresident & CEO, Director · 10 transactions | +86.8% | 23.9Kas of Nov 2024 | 20.8K | — | — |
| Veillon-Berteloot ChantalEVP & CHRO · 10 transactions | — | 22.2K | 33.1K | — | — |
| Poul MojdehPresident & CEO, Director · 4 transactions | — | 0 | 1.4K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: +82.7K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.